Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.

Abstract: An aircraft electrical system includes a controller system having a self-testing system configured to test an operability of a transient voltage suppression device. A single line communication bus is connected to a communications output of the controller. A first lightning protection device including the transient voltage suppression device is configured to protect the controller from transient voltages. An enable/disable circuit comprising a normally closed switch connects a low side of the lightning protection device to a neutral.

Abstract: A sensor interface includes a sensor circuit, a drive circuit connected to the sensor circuit with active and inactive states, and a back-bias circuit. The back-bias circuit is connected between the drive circuit and the sensor circuit. The back-bias circuit is arranged to allow current to flow from the drive circuit to the sensor circuit when the drive circuit is in the active state. The back-bias circuit is also arranged to limit current flow from the drive circuit to the sensor circuit when the drive circuit is in the inactive state. Sensor arrangements and open circuit detection methods are also described.

Abstract: An overvoltage protection arrangement includes a signal lead, a switch, and a comparator. The signal lead has a device segment and a bus segment. The switch is connected in series between the device segment and the bus segment. The comparator is operably connected to the switch to open the switch in response to sustained application of overvoltage to the bus segment of the signal lead. Aircraft electrical systems and methods of controlling voltage applied to electrical devices in electrical systems are also described.

Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.

Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.

Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.

Abstract: A sensor interface includes a sensor circuit, a drive circuit connected to the sensor circuit with active and inactive states, and a back-bias circuit. The back-bias circuit is connected between the drive circuit and the sensor circuit. The back-bias circuit is arranged to allow current to flow from the drive circuit to the sensor circuit when the drive circuit is in the active state. The back-bias circuit is also arranged to limit current flow from the drive circuit to the sensor circuit when the drive circuit is in the inactive state. Sensor arrangements and open circuit detection methods are also described.

Abstract: An aircraft electrical system includes a controller system having a self-testing system configured to test an operability of a transient voltage suppression device. A single line communication bus is connected to a communications output of the controller. A first lightning protection device including the transient voltage suppression device is configured to protect the controller from transient voltages. An enable/disable circuit comprising a normally closed switch connects a low side of the lightning protection device to a neutral.

Abstract: An overvoltage protection arrangement includes a signal lead, a switch, and a comparator. The signal lead has a device segment and a bus segment. The switch is connected in series between the device segment and the bus segment. The comparator is operably connected to the switch to open the switch in response to sustained application of overvoltage to the bus segment of the signal lead. Aircraft electrical systems and methods of controlling voltage applied to electrical devices in electrical systems are also described.

Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.

Abstract: Solid oral dosage forms of testosterone and methods for the preparation thereof are disclosed and described. The solid oral dosage form may include a therapeutically effective amount of testosterone in a substantially solid polyethylene glycol carrier. Such a form has been found to alleviate many of the undesirable consequences of undergoing testosterone therapy, such as the pain of injections and problems with patient noncompliance.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

Abstract: According to the inventive method of making gels, the main mixture comprising most of the ingredients with the exception of a fatty alcohol is mixed, using at least one in-line mixer, with the gelling post-mix comprising the fatty alcohol. The preferred process includes the mixing of the main mixture and the gelling post-mix just prior to either filling or storing the composition.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

Abstract: Solid oral dosage forms of testosterone and methods for the preparation thereof are disclosed and described. The solid oral dosage form may include a therapeutically effective amount of testosterone in a substantially solid polyethylene glycol carrier. Such a form has been found to alleviate many of the undesirable consequences of undergoing testosterone therapy, such as the pain of injections and problems with patient noncompliance.

Abstract: According to the inventive method of making gels, the main mixture comprising most of the ingredients with the exception of a fatty alcohol is mixed, using at least one in-line mixer, with the gelling post-mix comprising the fatty alcohol. The preferred process includes the mixing of the main mixture and the gelling post-mix just prior to either filling or storing the composition.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.